Feasibility and efficacy of low-dose pegfilgrastim for CD34+ cell mobilization in lymphoma.

Abstract

BACKGROUND:

Pegfilgrastim has equivalent efficacy to daily granulocyte colony-stimulating factor (G-CSF) in enhancing neutrophil recovery after chemotherapy, but data on its use for peripheral blood stem cell (PBSC) mobilization are limited. We evaluated the safety and efficacy of CD34+ PBSC mobilization by low-dose (3.6 mg) pegfilgrastim after chemotherapy in patients with malignant lymphoma.

STUDY DESIGN AND METHODS:

Twenty patients with malignant lymphoma were enrolled in this study. Cytotoxic chemotherapy was started on day 1, and 3.6 mg of pegfilgrastim was subcutaneously administered on day 7. CD34+ cells were counted in the peripheral blood daily from days 11 to 14 using a flow cytometric analysis.

RESULTS:

In 19 of the 20 patients (95%), the CD34+ cell counts in the peripheral blood exceeded 10 × 106/L, with a mean value of 20.3 on day 11, 38.0 on day 12, 40.3 on day 13, and 40.1 on day 14. Older age was associated with lower maximum CD34+ cell mobilization. The most frequent adverse events associated with pegfilgrastim were back pain, nausea, appetite loss, and lactate dehydrogenase elevation.

CONCLUSION:

Our data indicated that a single dose of 3.6 mg pegfilgrastim on day 7 after chemotherapy safely and effectively mobilized CD34+ cells.

• Authors: Hideki Goto, Daisuke Hidaka, Satoshi Yamamoto, Koji Hayasaka, Rie Michimata, Ikuko Kagawa, Kana Sunagoya, Hiroaki Iijima, Eiko Hayase, Souichi Shiratori, Kohei Okada, Junichi Sugita, Masahiro Onozawa, Daigo Hashimoto, Kaoru Kahata, Katsuya Fujimoto, Tomoyuki Endo, Chikara Shimizu, Takanori Teshima, North Japan Hematology Study Group (NJHSG)
• Journal: Journal of clinical apheresis (J Clin Apher) Vol. 35 Issue 5 Pg. 413-419 (Sep 2020) ISSN: 1098-1101 [Electronic] United States
• PMID: 33043486 (Publication Type: Journal Article)
• Copyright: © 2020 Wiley Periodicals LLC.

Chemical References

• pegfilgrastim
• Polyethylene Glycols
• Filgrastim

Topics

• Adult
• Aged
• Feasibility Studies
• Female
• Filgrastim (adverse effects, pharmacology)
• Hematopoietic Stem Cell Mobilization (methods)
• Humans
• Lymphoma (therapy)
• Male
• Middle Aged
• Peripheral Blood Stem Cell Transplantation (methods)
• Polyethylene Glycols (adverse effects, pharmacology)
• Prospective Studies